Microbial processes are crucial for producing biopharmaceuticals, vaccines, chemicals, and food ingredients. Continuous manufacturing could enhance efficiency and reduce footprint, but high bacterial mutation rates and technical complexity hinder its feasibility. No fully autonomous biopharmaceutical process has been submitted to the EMA/FDA, and large-scale plants consume excessive energy and water. As a result, no fully automated, continuous microbial bioprocess exists globally.
The Project!
The Econti project, funded by the Austrian Research Promotion Agency (FFG), is focused on increasing the efficiency, speed, and cost-effectiveness of biotechnological production. Within the project, a fully continuous, scalable bioprocess has been established for in E. coli based recombinant expression (Protein A) and purification at the 1–10 L scale.
The platform technology is designed to be product-agnostic within E.coli-based expression and scale-up to 100–1000 L. Contact us for more information!
The Key Innovations!
Genetic Stability Solution
enGenes Biotech’s patented technology ensures stable,
continuous recombinant protein production.
Integrated System
Two continuous fermentation reactors linked with a primary recovery unit and continuous chromatography established (enGenes Biotech & Tosoh). Automated unit operations using Qubicon® software (Qubicon AG).
Digital Twin Development
Hybrid models (Novasign) & fluid-dynamical models (SimVantage) for real-time monitoring and predictive control increase efficiency by reducing development and production time.
Cost & Sustainability Analysis
Techno-economic evaluation to model costs, efficiency, and environmental impact (BOKU).
The Partners
This page is hosted by Tosoh Bioscience on behalf of the Econti project partners. Project funded by Austrian Research Promotion Agency (FFG).
